|Chemical and physical data|
|Molar mass||143.1 kg/mol|
|(what is this?)|
Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech.
Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
- "Drozitumab". AdisInsight. Retrieved 31 January 2017.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|